Lindner M D, Gribkoff V K
Department of Neuropharmacology, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492.
Psychopharmacology (Berl). 1992;107(4):485-8. doi: 10.1007/BF02245260.
In the present study we have examined the effects of oral administration of BMY 21502, a potential cognition enhancing drug, on the impaired Morris water task performance of 16-18 month old F-344 rats. BMY 21502 did not affect swim speeds or performance on the first trial of each day, but it did increase the rate of acquisition and initial retention, resulting in decreased swim distances on the second trial of each day. This increased rate of acquisition was dose-dependent, increasing to a peak at 5.0 mg/kg; the effect was decreased at 10 mg/kg, but still above control values. These results suggest that BMY 21502 is orally active over a broad range of doses, and lend further support for its potential as a therapeutic agent for the treatment of dementia.
在本研究中，我们检测了口服一种潜在的认知增强药物BMY 21502对16 - 18月龄F - 344大鼠受损的莫里斯水迷宫任务表现的影响。BMY 21502不影响每日首次试验的游泳速度或表现，但它确实提高了习得率和初始记忆保持能力，导致每日第二次试验的游泳距离缩短。这种增加的习得率呈剂量依赖性，在5.0毫克/千克时增加到峰值；在10毫克/千克时效果减弱，但仍高于对照值。这些结果表明，BMY 21502在广泛的剂量范围内口服有效，并进一步支持了其作为治疗痴呆症治疗药物的潜力。
